NCT03850418View on ClinicalTrials.gov

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

February 20, 2026

Study Completion Date

February 20, 2026

Conditions
Myeloid Malignancy
Interventions
DRUG

azacitidine

azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated

Trial Locations (1)

48202

RECRUITING

Henry ford hospital, Detroit

All Listed Sponsors
lead

Henry Ford Health System

OTHER